MUMaki Urushihara

Maki Urushihara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maki Urushihara has a total of 143 co-authors. Here are the top co-authors by number of shared publications:

  • Shoji Kagami

    Department of Pediatrics, Institute of Health Biosciences The Tokushima University Graduate School Tokushima Japan

    8 shared publications
  • Shuji Kondo

    Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

    6 shared publications
  • Takashi Nagai

    Department of Pediatrics, Institute of Health Biosciences The Tokushima University Graduate School Tokushima Japan

    4 shared publications
  • Yukiko Kinoshita

    Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan

    4 shared publications
  • Ariunbold Jamba

    Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan

    3 shared publications
  • Keisuke Fujioka

    Department of Pediatrics, Institute of Health Biosciences The Tokushima University Graduate School Tokushima Japan

    3 shared publications

Latest Publications

  • Open Access

    Clinical practice guideline for pediatric IgA vasculitis in Japan 2023: a digest-secondary publication

    by Masaki Shimizu, Kandai Nozu, Koichi Kamei, Satoru Arai, Shinichi Ansai, Toru Igarashi, Takashi Ishige, Maki Urushihara, Toshiyuki Ohta, Masafumi Oka, et al.


  • Open Access

    The role of the renin-angiotensin system in pediatric kidney diseases and neonatal development

    by Maki Urushihara

    The local renal renin-angiotensin system (RAS) is regulated independently of the systemic RAS. The renal RAS not only regulates blood pressure and hemodynamics but also plays an important role in the kidney disease development. Many studies have shown that the of angiotensinogen urinary excretion rate is a specific index of the intrarenal RAS activation. Moreover, urinary angiotensinogen (AGT) levels reflect the intrarenal RAS status associated with hypertension, chronic kidney disease, and diabetic nephropathy. In addition, urinary AGT is a novel biomarker of intrarenal RAS activation during neonatal kidney development. Furthermore, angiotensin-converting enzyme 2 and the (pro)renin receptor have recently been identified as new components of the RAS that have novel functions in kidney diseases and development. This review summarizes the current knowledge on intrarenal RAS activation in the context of pathological and physiological processes in children. J. Med. Invest. 72 : 241-244, August, 2025

  • Open Access

    A case of recurrent systemic lupus erythematosus in a boy with antiphospholipid syndrome nephropathy

    by Yuki Sakaki, Tomoki Hattori, Keisuke Fujioka, Takashi Nagai, Maki Urushihara, Hideko Endo, Hisanori Uehara

    症例は16歳,男子.2年前に全身性エリテマトーデス,ループス腎炎class IV-G(A)と診断した.メチルプレドニゾロンパルス療法,経口プレドニゾロン(PSL),ヒドロキシクロロキン(HCQ),ミコフェノール酸モフェチル(MMF)を併用し寛解に至るも,7か月後より治療を自己中断した.その1年後に発熱,全身浮腫をきたし当院を受診した.高血圧,腎機能障害,高度蛋白尿を認め,腎病理組織はclass IV-G(A)で血管極や係蹄内の血栓,フィブリノイド壊死が認められた.溶血性貧血の所見はなかったが,血栓性微小血管障害症,つまり抗リン脂質抗体症候群腎症(APSN)に特徴的な所見であった.PSLを開始,メチルプレドニゾロンパルス療法3クールを施行した.寛解維持のためHCQ, MMFも追加し,再発後約1年半が経過した現在も内服継続中である.本症例では腎機能障害が遷延しており,慢性腎臓病への移行が懸念される.

  • Renin‐angiotensin blockade ameliorates the progression of glomerular injury in podocyte‐specific Ctcf knockout mice

    by Keisuke Fujioka, Takashi Nagai, Tomoki Hattori, Shoji Kagami, Koji Yasutomo, Niels Galjart, Teruyoshi Hirayama, Hiroshi Kawachi, Maki Urushihara

    Aim: Several studies have shown that the progression of proteinuria and renal tissue injury is associated with activation of the intrarenal renin‐angiotensin system (RAS). CCCTC‐binding factor (CTCF) is a DNA‐binding factor that plays an essential role in the regulation of gene expression. In the present study, we aimed to investigate the phenotypic effects of CTCF deficiency in podocytes.Methods: Angiotensin II type 1 receptor blockers (ARBs) were administered to the podocyte‐specific Ctcf knockout mice, and histological and biochemical analyzes were performed. We also investigated the changes in the expression of podocin in podocyte cell cultures with or without stimulation with angiotensin II from glomeruli isolated using magnetic beads from podocyte‐specific Ctcf knockout mice.Results: Mice in which Ctcf was deleted from podocytes developed glomerulopathy and mice developed severe progressive proteinuria, and impaired renal function. Moreover, ARBs suppressed the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Both real‐time polymerase chain reaction and western blotting showed that podocin expression was decreased in cell cultures stimulated with angiotensin II. Furthermore, RAS components gene expressions in podocyte cell cultures isolated from podocyte‐specific Ctcf knockout mice were significantly increased.Conclusion: These results suggest that RAS is involved in the development of glomerulopathy in podocyte‐specific Ctcf knockout mice. Elucidation of the pathophysiology of podocyte‐specific Ctcf knockout mice may provide new insights into the relationship between podocyte injury and chronic glomerulonephritis. image

  • A female case of L1 syndrome that may have developed due to skewed X inactivation

    by Tatsuo Mori, Mutsuki Nakano, Takahiro Tayama, Aya Goji, Yoshihiro Toda, Shinichi Kameyama, Takeshi Mizuguchi, Maki Urushihara, Naomichi Matsumoto

  • Open Access

    Intrarenal renin–angiotensin system activation and macrophage infiltrations in pediatric chronic glomerulonephritis

    by Tomoki Hattori, Keisuke Fujioka, Takashi Nagai, Shuji Kondo, Shoji Kagami, Masahiro Hirayama, Maki Urushihara

    Background: The current study tested the hypothesis that urinary angiotensinogen (UAGT) and urinary monocyte chemoattractant protein-1 (UMCP-1) levels provide a specific index of intrarenal renin–angiotensin system (RAS) status and the degree of infiltration of macrophages associated with RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis. Methods: We measured baseline UAGT and UMCP-1 levels to examine the correlation between glomerular injury in 48 pediatric chronic glomerulonephritis patients before treatment. Furthermore, we performed immunohistochemical analysis of angiotensinogen (AGT) and CD68 in 27 pediatric chronic glomerulonephritis patients treated with RAS blockades and immunosuppressants for 2 years. Finally, we examined the effects of angiotensin II (Ang II) on monocyte chemoattractant protein-1 (MCP-1) expression in cultured human mesangial cells (MCs). Results: Baseline UAGT and UMCP-1 levels positively correlated with urinary protein levels, scores for mesangial hypercellularity, rate of crescentic formation, and expression levels of AGT and CD68 in renal tissues (p < 0.05). UAGT and UMCP-1 levels were significantly decreased after RAS blockade and immunosuppressant treatment (p < 0.01), which was accompanied by AGT and CD68 (p < 0.01), as well as the magnitude of glomerular injury. Cultured human MCs showed increased MCP-1 messenger ribonucleic acid and protein levels after Ang II treatment (p < 0.01). Conclusions: The data indicates that UAGT and UMCP-1 are useful biomarkers of the degree of glomerular injury during RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis.


  • Clinical and histological features in pediatric and adolescent/young adult patients with renal disease: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR)

    by Maki Urushihara, Hiroshi Sato, Akira Shimizu, Hitoshi Sugiyama, Hitoshi Yokoyama, Hiroshi Hataya, Kentaro Matsuoka, Takayuki Okamoto, Daisuke Ogino, Kenichiro Miura, et al.

    Background Only a few studies have investigated epidemiological and clinicopathological information regarding pediatric and adolescent and young adult (AYA) patients with renal disease. The purpose of this study was to clarify the differences and relationship of clinicopathological findings between pediatric and AYA patients using the Japan Renal Biopsy Registry (J-RBR). Methods This cross-sectional study analyzed data from patients registered in the J-RBR between 2007 and 2017. Clinicopathological findings at diagnosis were analyzed for 3,463 pediatric (age < 15 years) and 6,532 AYA (age 15–30 years) patients. Results Although chronic nephritic syndrome was the most common clinical diagnosis at age > 5 years, nephrotic syndrome was the most frequent diagnosis at age < 4 years. The most common pathological diagnosis as classified by pathogenesis in pediatric patients was primary glomerular disease (except IgA nephropathy), whereas IgA nephropathy was increased in AYA patients. Mesangial proliferative glomerulonephritis was the most common pathological diagnosis as classified by histopathology in both pediatric and AYA patients. Minor glomerular abnormalities were the most frequent histopathologic diagnoses of nephrotic syndrome in childhood, but their frequency decreased with age. Conclusion To the best of our knowledge, this is the first report of clinicopathological features of pediatric and AYA patients in a large nationwide registry of renal biopsy. There were differences of clinical, pathological and histopathologic findings between pediatric and AYA patients.


  • (Pro)renin receptor promotes crescent formation via the ERK1/2 and Wnt/β-catenin pathways in glomerulonephritis

    by Maki Urushihara, Shuji Kondo, Yukiko Kinoshita, Natsuko Ozaki, Ariunbold Jamba, Takashi Nagai, Keisuke Fujioka, Tomoki Hattori, Shouji Kagami

    (Pro)renin receptor [(P)RR] has multiple functions, but its regulation and role in the pathogenesis in glomerulonephritis (GN) are poorly defined. The aims of the present study were to determine the effects of direct renin inhibition (DRI) and demonstrate the role of (P)RR on the progression of crescentic GN. The anti-glomerular basement membrane nephritis rat model developed progressive proteinuria (83.64 ± 10.49 mg/day) and glomerular crescent formation (percent glomerular crescent: 62.1 ± 2.3%) accompanied by increased macrophage infiltration and glomerular expression of monocyte chemoattractant protein (MCP)-1, (P)RR, phospho-extracellular signal-regulated kinase (ERK)1/2, Wnt4, and active β-catenin. Treatment with DRI ameliorated proteinuria (20.33 ± 5.88 mg/day) and markedly reduced glomerular crescent formation (20.9 ± 2.6%), induction of macrophage infiltration, (P)RR, phospho-ERK1/2, Wnt4, and active β-catenin. Furthermore, primary cultured parietal epithelial cells stimulated by recombinant prorenin showed significant increases in cell proliferation. Notably, while the ERK1/2 inhibitor PD98059 or (P)RR-specific siRNA treatment abolished the elevation in cell proliferation, DRI treatment did not abrogate this elevation. Moreover, cultured mesangial cells showed an increase in prorenin-induced MCP-1 expression. Interestingly, (P)RR or Wnt4-specific siRNA treatment or the β-catenin antagonist XAV939 inhibited the elevation of MCP-1 expression, whereas DRI did not. These results suggest that (P)RR regulates glomerular crescent formation via the ERK1/2 signaling and Wnt/β-catenin pathways during the course of anti-glomerular basement membrane nephritis and that DRI mitigates the progression of crescentic GN through the reduction of (P)RR expression but not inhibition of prorenin binding to (P)RR.


  • Enhanced angiotensinogen expression in neonates during kidney development

    by Miki Shono, Maki Urushihara, Kenichi Suga, Noriko Watanabe, Takahiko Saijo, Ryuji Nakagawa, Shoji Kagami

    We recently demonstrated that preterm neonates have higher urinary angiotensinogen (AGT) levels than full-term neonates. Here, we tested the hypothesis that enhanced neonatal AGT expression is associated with intrarenal renin–angiotensin system (RAS) status during kidney development.


  • Diversity of renal phenotypes in patients with WDR19 mutations: Two case reports

    by Takahisa Yoshikawa, Koichi Kamei, Hiroko Nagata, Ken Saida, Mai Sato, Masao Ogura, Shuichi Ito, Osamu Miyazaki, Maki Urushihara, Shuji Kondo, et al.

    WDR19 has been reported as a causative gene of nephronophthisis‐related ciliopathies. Patients with WDR19 mutations can show various extrarenal manifestations such as skeletal disorders, Caroli disease, and retinal dystrophy, and typically display nephronophthisis as a renal phenotype. However, there is limited information on the renal phenotypes of patients with WDR19 mutations. We report two Japanese infants with Sensenbrenner syndrome caused by WDR19 mutations who demonstrated different features in renal ultrasound and histopathological results, despite several common extrarenal manifestations. Patient 1 had normal sized and hyperechogenic kidneys with several small cysts and histopathological findings compatible with infantile nephronophthisis. Renal ultrasound of Patient 2 showed enlarged kidneys with diffuse microcysts resembling those of autosomal recessive polycystic kidney disease. Her renal histopathology revealed dysplastic kidney with diffuse glomerular cysts. Genetic testing identified compound heterozygous mutations in WDR19 in both patients (Patient 1: c.953delA, c.3533G > A, Patient 2: c.2645 + 1G > T, c.3533G > A). Our patients suggest that WDR19 mutations can cause dysplastic kidney in addition to nephronophthisis pathologically. In addition, differences in pathology of the kidneys from WDR19 mutations may result in heterogeneous features in renal ultrasound findings. Renal phenotypes from WDR19 mutations may thus be more diverse than previously reported. Extrarenal manifestations and genetic testing can therefore help to diagnosis this disease more precisely.